Demand for new obesity drug outstripping supply

Demand for Novo Nordisk's Wegovy, the first new obesity drug approved in seven years, is exceeding supply, according to Bloomberg.

The weekly injection, approved by the FDA in June, works by decreasing a person's appetite and has been shown in clinical trials to help people lose an average of 15 percent of their body weight.